Johnson & Johnson announced that its head and neck cancer treatment has received ‘Breakthrough Therapy Designation’ from the U.S. FDA. This designation aims to expedite the development and review of drugs for serious or life-threatening conditions. The news was reported by MT Newswires.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Johnson & Johnson Says Head and Neck Cancer Treatment Given US FDA 'Breakthrough Therapy Designation'
Johnson & Johnson announced that its head and neck cancer treatment has received ‘Breakthrough Therapy Designation’ from the U.S. FDA. This designation aims to expedite the development and review of drugs for serious or life-threatening conditions. The news was reported by MT Newswires.